Our results suggest that a combinatorial approach that inhibits both EGFR and IGF1R signaling may offer a worthy strategy to enhance therapeutic outcome and combat acquired resistance to cetuximab in head and neck cancer. Here, EGFR is linked to head and neck cancer.